NASDAQ:MCRB - Seres Therapeutics Stock Price, Price Target & More

$7.73 -0.17 (-2.15 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$7.90
Today's Range$7.65 - $8.05
52-Week Range$6.65 - $17.42
Volume74,799 shs
Average Volume150,626 shs
Market Capitalization$341.45 million
P/E Ratio-3.50
Dividend YieldN/A
Beta0.51

About Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics logoSeres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

Receive MCRB News and Ratings via Email

Sign-up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MCRB
CUSIPN/A
Phone617-945-9626

Debt

Debt-to-Equity Ratio0.15%
Current Ratio4.90%
Quick Ratio4.90%

Price-To-Earnings

Trailing P/E Ratio-3.50
Forward P/E Ratio-2.92
P/E GrowthN/A

Sales & Book Value

Annual Sales$32.10 million
Price / Sales9.79
Cash FlowN/A
Price / CashN/A
Book Value$1.50 per share
Price / Book5.15

Profitability

EPS (Most Recent Fiscal Year)($2.21)
Net Income$-89,380,000.00
Net Margins-278.44%
Return on Equity-103.46%
Return on Assets-41.45%

Miscellaneous

Employees138
Outstanding Shares40,650,000

How to Become a New Pot Stock Millionaire

Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics Inc (NASDAQ:MCRB) issued its quarterly earnings results on Thursday, March, 8th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.73) by $0.02. The biotechnology company earned $3.06 million during the quarter, compared to analyst estimates of $3 million. Seres Therapeutics had a negative return on equity of 103.46% and a negative net margin of 278.44%. View Seres Therapeutics' Earnings History.

When is Seres Therapeutics' next earnings date?

Seres Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Seres Therapeutics.

What price target have analysts set for MCRB?

8 Wall Street analysts have issued 1 year price objectives for Seres Therapeutics' stock. Their forecasts range from $16.00 to $20.00. On average, they expect Seres Therapeutics' share price to reach $18.8571 in the next twelve months. View Analyst Ratings for Seres Therapeutics.

What are Wall Street analysts saying about Seres Therapeutics stock?

Here are some recent quotes from research analysts about Seres Therapeutics stock:
  • 1. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (3/14/2018)
  • 2. Cowen Inc analysts commented, "Seres reported top-line results from a Phase 1b trial of SER-287 in 58 patients with." (10/2/2017)

Who are some of Seres Therapeutics' key competitors?

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the folowing people:
  • Roger Pomerantz M.D., Chairman of the Board, President, Chief Executive Officer (Age 60)
  • Eric D. Shaff, Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer (Age 42)
  • John G. Aunins Ph.D., Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing (Age 56)
  • David N. Cook Ph.D., Chief Scientific Officer, Executive Vice President - Research & Development (Age 59)
  • Thomas J. DesRosier J.D., Chief Legal Officer, Executive Vice President and Secretary (Age 62)
  • Michele Trucksis Ph.D. M.D., Chief Medical Officer and Executive Vice President (Age 64)
  • Noubar B. Afeyan, Lead Independent Director (Age 55)
  • Willard H. Dere M.D., Director (Age 63)
  • Dennis A. Ausiello M.D., Independent Director (Age 71)
  • Gregory Behar, Independent Director (Age 49)

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Has Seres Therapeutics been receiving favorable news coverage?

News coverage about MCRB stock has been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Seres Therapeutics earned a news impact score of 0.23 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 44.94 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include NESTLE HEALTH SCIENCE US HOLDINGS, INC. (16.97%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis, Roger Pomerantz and Ventures Fund 2007 L Flagship. View Institutional Ownership Trends for Seres Therapeutics.

How do I buy shares of Seres Therapeutics?

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $7.73.

How big of a company is Seres Therapeutics?

Seres Therapeutics has a market capitalization of $341.45 million and generates $32.10 million in revenue each year. The biotechnology company earns $-89,380,000.00 in net income (profit) each year or ($2.21) on an earnings per share basis. Seres Therapeutics employs 138 workers across the globe.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626.


MarketBeat Community Rating for Seres Therapeutics (MCRB)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  360
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe MCRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MCRB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Seres Therapeutics (NASDAQ:MCRB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Seres Therapeutics in the last 12 months. Their average twelve-month price target is $18.8571, suggesting that the stock has a possible upside of 143.95%. The high price target for MCRB is $20.00 and the low price target for MCRB is $16.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.8571$18.8571$18.75$18.75
Price Target Upside: 143.95% upside73.48% upside72.49% upside72.49% upside

Seres Therapeutics (NASDAQ:MCRB) Consensus Price Target History

Price Target History for Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics (NASDAQ:MCRB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2017CIBCInitiated CoverageOutperform -> Outperform$19.00N/AView Rating Details
10/12/2017OppenheimerInitiated CoverageOutperform$19.00N/AView Rating Details
10/12/2017CitigroupInitiated CoverageOutperform -> Positive$19.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$20.00N/AView Rating Details
10/2/2017CowenReiterated RatingBuyHighView Rating Details
8/30/2017Cantor FitzgeraldReiterated RatingBuyLowView Rating Details
8/4/2017HC WainwrightReiterated RatingBuy -> Buy$15.00 -> $19.00HighView Rating Details
8/3/2017Canaccord GenuitySet Price TargetBuy$20.00LowView Rating Details
3/20/2017FBR & CoReiterated RatingOutperform$18.00LowView Rating Details
8/11/2016Leerink SwannReiterated RatingBuy$12.00N/AView Rating Details
8/1/2016Bank of AmericaDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Seres Therapeutics (NASDAQ:MCRB) Earnings History and Estimates Chart

Earnings by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics (NASDAQ:MCRB) Earnings Estimates

2018 EPS Consensus Estimate: ($2.65)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.64)($0.64)($0.64)
Q2 20181($0.65)($0.65)($0.65)
Q3 20181($0.67)($0.67)($0.67)
Q4 20181($0.69)($0.69)($0.69)
Q1 20191($0.73)($0.73)($0.73)
Q2 20191($0.24)($0.24)($0.24)
Q3 20191($0.29)($0.29)($0.29)

Seres Therapeutics (NASDAQ MCRB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($0.63)N/AView Earnings Details
3/8/2018Q4 2017($0.73)($0.71)$3.00 million$3.06 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.39)($0.17)$17.29 million$23.00 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.59)($0.69)$3.00 million$3.00 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.65)($0.63)$3.00 million$3.02 millionViewListenView Earnings Details
3/16/2017Q4 2016($0.70)($0.6260)$3.00 million$3.00 millionViewN/AView Earnings Details
11/10/2016Q316($0.55)($0.46)$10.38 million$13.02 millionViewListenView Earnings Details
8/11/2016Q216($0.46)($0.70)$4.20 million$3.00 millionViewListenView Earnings Details
5/16/2016Q116($0.48)($0.50)$1.25 million$2.71 millionViewListenView Earnings Details
2/25/2016Q4 2015($0.40)($0.41)ViewN/AView Earnings Details
11/10/2015Q315($0.32)($0.38)ViewListenView Earnings Details
8/6/2015Q215($0.30)($1.45)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Seres Therapeutics (NASDAQ:MCRB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Seres Therapeutics (NASDAQ MCRB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 41.90%
Institutional Ownership Percentage: 79.02%
Insider Trading History for Seres Therapeutics (NASDAQ:MCRB)
Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics (NASDAQ MCRB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/26/2018David N CookInsiderSell1,738$11.02$19,152.76141,673View SEC Filing  
12/19/2017John G AuninsInsiderSell1,623$10.14$16,457.2261,060View SEC Filing  
8/29/2016John G AuninsInsiderSell9,390$10.87$102,069.30192,125View SEC Filing  
7/28/2016Michele TrucksisInsiderSell4,156$35.18$146,208.084,156View SEC Filing  
7/27/2016Michele TrucksisInsiderSell38,064$35.14$1,337,568.9638,064View SEC Filing  
7/25/2016John G AuninsInsiderSell9,390$34.18$320,950.20220,155View SEC Filing  
7/6/2016Roger PomerantzCEOSell88,211$29.45$2,597,813.95236,468View SEC Filing  
7/1/2016Roger PomerantzCEOSell56,789$29.81$1,692,880.09240,481View SEC Filing  
6/30/2016Eric D ShaffCFOSell4,533$29.54$133,904.824,533View SEC Filing  
6/28/2016Eric D ShaffCFOSell5,001$28.28$141,428.283,334View SEC Filing  
6/27/2016John G AuninsEVPSell9,390$27.23$255,689.7032,655View SEC Filing  
6/2/2016David N CookEVPSell8,000$31.00$248,000.00136,673View SEC Filing  
6/2/2016Roger PomerantzCEOSell74,049$32.52$2,408,073.48257,741View SEC Filing  
6/1/2016David N CookEVPSell16,000$29.43$470,880.00144,673View SEC Filing  
6/1/2016Roger PomerantzCEOSell70,951$30.51$2,164,715.01254,643View SEC Filing  
5/25/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell1,000,000$27.60$27,600,000.00View SEC Filing  
5/24/2016Roger PomerantzCEOSell9,801$30.00$294,030.00193,493View SEC Filing  
5/6/2016Roger PomerantzCEOSell8,507$24.31$206,805.1731,234View SEC Filing  
5/5/2016Roger PomerantzCEOSell59,325$26.13$1,550,162.2551,325View SEC Filing  
5/3/2016Roger PomerantzCEOSell67,367$28.70$1,933,432.9066,414View SEC Filing  
4/25/2016John G AuninsEVPSell18,640$31.94$595,361.6056,060View SEC Filing  
4/7/2016David N CookEVPSell8,000$31.00$248,000.00160,673View SEC Filing  
4/7/2016Roger PomerantzCEOSell9,212$30.00$276,360.0024,439View SEC Filing  
4/4/2016David N CookEVPSell61,000$26.16$1,595,760.00183,023View SEC Filing  
4/4/2016Eric D ShaffCFOSell6,568$28.85$189,486.806,568View SEC Filing  
4/4/2016Roger PomerantzCEOSell135,788$27.20$3,693,433.60113,690View SEC Filing  
3/31/2016Eric D ShaffCFOSell7,663$26.30$201,536.907,663View SEC Filing  
3/28/2016Eric D ShaffCFOSell5,473$24.07$131,735.115,473View SEC Filing  
3/28/2016John G AuninsEVPSell9,390$23.89$224,327.1074,700View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Seres Therapeutics (NASDAQ MCRB) News Headlines

Source:
DateHeadline
Seres Therapeutics (MCRB) Rating Increased to Buy at Zacks Investment ResearchSeres Therapeutics (MCRB) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 19 at 8:31 PM
Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual MeetingSeres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 17 at 6:03 PM
Seres Therapeutics (MCRB) Raised to "Buy" at BidaskClubSeres Therapeutics (MCRB) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - April 16 at 9:16 AM
Seres Therapeutics (MCRB) Rating Increased to Hold at ValuEngineSeres Therapeutics (MCRB) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 14 at 8:35 PM
Seres Therapeutics (MCRB) Lifted to "Sell" at BidaskClubSeres Therapeutics (MCRB) Lifted to "Sell" at BidaskClub
www.americanbankingnews.com - April 13 at 11:03 AM
Seres Therapeutics (MCRB) Downgraded by Zacks Investment ResearchSeres Therapeutics (MCRB) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 12 at 10:46 PM
$3.00 Million in Sales Expected for Seres Therapeutics Inc (MCRB) This Quarter$3.00 Million in Sales Expected for Seres Therapeutics Inc (MCRB) This Quarter
www.americanbankingnews.com - April 12 at 5:05 AM
Seres Therapeutics Inc (MCRB) Expected to Announce Earnings of -$0.74 Per ShareSeres Therapeutics Inc (MCRB) Expected to Announce Earnings of -$0.74 Per Share
www.americanbankingnews.com - April 10 at 3:13 AM
Seres Therapeutics wins dismissal of investor lawsuit over drug studySeres Therapeutics wins dismissal of investor lawsuit over drug study
www.reuters.com - April 3 at 5:40 PM
Seres Therapeutics Inc (MCRB) Given Average Recommendation of "Buy" by BrokeragesSeres Therapeutics Inc (MCRB) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 31 at 1:36 AM
Zacks Investment Research Lowers Seres Therapeutics (MCRB) to HoldZacks Investment Research Lowers Seres Therapeutics (MCRB) to Hold
www.americanbankingnews.com - March 30 at 10:02 PM
Seres Therapeutics (MCRB) Lowered to Strong Sell at BidaskClubSeres Therapeutics (MCRB) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - March 28 at 10:44 AM
Zacks: Brokerages Expect Seres Therapeutics Inc (MCRB) Will Post Quarterly Sales of $3.00 MillionZacks: Brokerages Expect Seres Therapeutics Inc (MCRB) Will Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - March 26 at 8:04 AM
BidaskClub Lowers Seres Therapeutics (MCRB) to SellBidaskClub Lowers Seres Therapeutics (MCRB) to Sell
www.americanbankingnews.com - March 25 at 9:51 AM
Edited Transcript of MCRB earnings conference call or presentation 8-Mar-18 1:00pm GMTEdited Transcript of MCRB earnings conference call or presentation 8-Mar-18 1:00pm GMT
finance.yahoo.com - March 18 at 6:27 PM
Zacks Investment Research Upgrades Seres Therapeutics (MCRB) to "Hold"Zacks Investment Research Upgrades Seres Therapeutics (MCRB) to "Hold"
www.americanbankingnews.com - March 18 at 10:32 AM
FY2018 EPS Estimates for Seres Therapeutics Inc (MCRB) Lifted by Cantor FitzgeraldFY2018 EPS Estimates for Seres Therapeutics Inc (MCRB) Lifted by Cantor Fitzgerald
www.americanbankingnews.com - March 14 at 10:28 AM
Research Analysts Issue Forecasts for Seres Therapeutics Incs FY2019 Earnings (MCRB)Research Analysts Issue Forecasts for Seres Therapeutics Inc's FY2019 Earnings (MCRB)
www.americanbankingnews.com - March 13 at 3:07 PM
Seres Therapeutics (MCRB) Upgraded to "Hold" at Zacks Investment ResearchSeres Therapeutics (MCRB) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 11 at 2:07 PM
Seres Therapeutics (MCRB) Cut to "Sell" at BidaskClubSeres Therapeutics (MCRB) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - March 10 at 5:28 PM
Seres Therapeutics (MCRB) Releases  Earnings Results, Beats Estimates By $0.02 EPSSeres Therapeutics (MCRB) Releases Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - March 9 at 4:15 PM
Seres Therapeutics to Present at Two Upcoming March Conferences - Business Wire (press release)Seres Therapeutics to Present at Two Upcoming March Conferences - Business Wire (press release)
www.businesswire.com - March 9 at 8:12 AM
Seres Therapeutics to Present at Two Upcoming March ConferencesSeres Therapeutics to Present at Two Upcoming March Conferences
finance.yahoo.com - March 9 at 8:12 AM
Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates - Business Wire (press release)Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates - Business Wire (press release)
www.businesswire.com - March 8 at 8:15 AM
Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdatesSeres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
finance.yahoo.com - March 8 at 8:15 AM
Seres Therapeutics Inc to Host Earnings CallSeres Therapeutics Inc to Host Earnings Call
finance.yahoo.com - March 8 at 8:15 AM
Seres Therapeutics Inc (MCRB) Expected to Post Quarterly Sales of $3.00 MillionSeres Therapeutics Inc (MCRB) Expected to Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - March 8 at 2:02 AM
Seres Therapeutics (MCRB) Set to Announce Earnings on WednesdaySeres Therapeutics (MCRB) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 7 at 1:50 AM
Seres Therapeutics Inc (MCRB) Expected to Announce Earnings of -$0.73 Per ShareSeres Therapeutics Inc (MCRB) Expected to Announce Earnings of -$0.73 Per Share
www.americanbankingnews.com - March 6 at 9:22 PM
Seres Therapeutics Inc (MCRB) Given Average Rating of "Buy" by AnalystsSeres Therapeutics Inc (MCRB) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - March 6 at 1:36 AM
Citadel Advisors LLC Buys New Position in Seres Therapeutics Inc (MCRB)Citadel Advisors LLC Buys New Position in Seres Therapeutics Inc (MCRB)
www.americanbankingnews.com - March 3 at 5:20 AM
Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and ... - Business Wire (press release)Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and ... - Business Wire (press release)
www.businesswire.com - March 2 at 8:09 AM
Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on March 8, 2018Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on March 8, 2018
finance.yahoo.com - March 2 at 8:09 AM
Report: Developing Opportunities within AeroVironment, Seres Therapeutics, HFF, Fluor, KB Home, and H. B. Fuller — Future Expectations, Projections Moving into 2018Report: Developing Opportunities within AeroVironment, Seres Therapeutics, HFF, Fluor, KB Home, and H. B. Fuller — Future Expectations, Projections Moving into 2018
finance.yahoo.com - February 26 at 8:11 AM
ARK Investment Management LLC Acquires 732,579 Shares of Seres Therapeutics Inc (MCRB)ARK Investment Management LLC Acquires 732,579 Shares of Seres Therapeutics Inc (MCRB)
www.americanbankingnews.com - February 26 at 5:12 AM
Seres Therapeutics (MCRB) Upgraded at BidaskClubSeres Therapeutics (MCRB) Upgraded at BidaskClub
www.americanbankingnews.com - February 24 at 4:30 PM
Seres Therapeutics Inc (MCRB) Expected to Post Earnings of -$0.73 Per ShareSeres Therapeutics Inc (MCRB) Expected to Post Earnings of -$0.73 Per Share
www.americanbankingnews.com - February 18 at 5:08 AM
Financial Analysis: Seres Therapeutics (MCRB) versus Its RivalsFinancial Analysis: Seres Therapeutics (MCRB) versus Its Rivals
www.americanbankingnews.com - February 5 at 9:48 AM
Zacks: Analysts Anticipate Seres Therapeutics Inc (MCRB) Will Post Quarterly Sales of $3.00 MillionZacks: Analysts Anticipate Seres Therapeutics Inc (MCRB) Will Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - February 3 at 6:56 AM
Seres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating OfficerSeres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating Officer
finance.yahoo.com - January 31 at 9:03 AM
David N. Cook Sells 1,738 Shares of Seres Therapeutics Inc (MCRB) StockDavid N. Cook Sells 1,738 Shares of Seres Therapeutics Inc (MCRB) Stock
www.americanbankingnews.com - January 30 at 9:18 PM
Seres Therapeutics (MCRB) and Its Competitors Head-To-Head SurveySeres Therapeutics (MCRB) and Its Competitors Head-To-Head Survey
www.americanbankingnews.com - January 18 at 3:28 PM
Seres Therapeutics Inc (MCRB) Expected to Announce Quarterly Sales of $3.00 MillionSeres Therapeutics Inc (MCRB) Expected to Announce Quarterly Sales of $3.00 Million
www.americanbankingnews.com - January 17 at 2:50 PM
Critical Contrast: Verastem (VSTM) vs. Seres Therapeutics (MCRB)Critical Contrast: Verastem (VSTM) vs. Seres Therapeutics (MCRB)
www.americanbankingnews.com - January 15 at 1:16 PM
Seres Therapeutics Inc (MCRB) Given Average Rating of "Buy" by BrokeragesSeres Therapeutics Inc (MCRB) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 15 at 1:38 AM
Comparing Seres Therapeutics (MCRB) & The CompetitionComparing Seres Therapeutics (MCRB) & The Competition
www.americanbankingnews.com - January 14 at 1:42 PM
Financial Comparison: Catabasis Pharmaceuticals (CATB) versus Seres Therapeutics (MCRB)Financial Comparison: Catabasis Pharmaceuticals (CATB) versus Seres Therapeutics (MCRB)
www.americanbankingnews.com - January 8 at 11:06 PM
Seres Therapeutics Inc to Post FY2022 Earnings of ($0.30) Per Share, Oppenheimer Forecasts (MCRB)Seres Therapeutics Inc to Post FY2022 Earnings of ($0.30) Per Share, Oppenheimer Forecasts (MCRB)
www.americanbankingnews.com - January 8 at 8:40 PM
Seres Therapeutics (MCRB) Announces SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for ... - StreetInsider.comSeres Therapeutics (MCRB) Announces SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for ... - StreetInsider.com
www.streetinsider.com - January 5 at 4:50 PM
Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare ConferenceSeres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:45 AM

SEC Filings

Seres Therapeutics (NASDAQ:MCRB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Seres Therapeutics (NASDAQ:MCRB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Seres Therapeutics (NASDAQ MCRB) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.